The Role of 5-Alpha-Reductase Inhibitors in Active Surveillance

    March 2012 in “ Current opinion in urology ”
    David Margel, Neil Fleshner
    TLDR 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
    The document discussed the role of 5-alpha-reductase inhibitors (5-ARIs) in active surveillance for men with low-risk prostate cancer (PCa). It highlighted that active surveillance is a preferred treatment for favorable risk PCa, but 30-50% of men on this path eventually require therapy due to disease progression. Recent findings from two studies, including a multicenter randomized controlled study, indicated that 5-ARIs might reduce the rate of clinical progression in these patients. However, these results needed to be interpreted cautiously due to the recent US FDA recommendation against labeling 5-ARIs for PCa chemoprevention.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    5 / 1000+ results
      Table 1

      research Table 1

      December 2021
      Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
      Table 2

      research Table 2

      December 2021
      Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.